Echinaforce® by A. Vogel acts by modulating the immune system to help reduce the inflammatory response to viral attacks and activate the body's antiviral defenses to prevent infection - especially in more vulnerable individuals such as the elderly, children, people under high stress or fatigue, and smokers.
Echinaforce® by A. Vogel has a long-standing reputation for efficacy and safety, demonstrated by over 30 clinical studies, ranging from in vitro to randomized, double-blind, placebo-controlled studies.
Echinaforce® is officially approved by Health Canada for the following:
- Echinaforce® is clinically proven to help prevent and relieve symptoms of upper respiratory tract infections (URTIs), such as colds and flu. Reduces the duration of URTIs. Used in phytotherapy to support the immune system, particularly in times of stress, sleep deprivation or in smokers.
- Echinaforce® can be taken daily for 4 months as a preventive measure.
Echinaforce®: in vitro activity against common viral infections
An in vitro study, published in the Virology Journal in September 2020, measured the impact of Echinaforce® against enveloped viruses, including members of the coronavirus family such as MERS, SARS-CoV-1 and common cold HCoV-229E.
The study was carried out by independent researchers at the Spiez laboratory in Switzerland. Cell experiments showed positive preliminary results on antiviral activity.
While the authors conclude that "Echinaforce® could be effective as a preventive treatment for all CoVs due to their structural similarities", these results have yet to be confirmed in human clinical trials.
